Frequently Asked Questions
The global non-hodgkin lymphoma therapeutics market was valued at USD 8.5 Billion in 2022.
The non-hodgkin lymphoma therapeutics market is expected to grow at a CAGR of 8.80% between 2023 and 2030, reaching USD 15.34 Billion in 2030.
Radiation therapy is the leading segment by type of therapy, holding over 43% share in terms of value in 2022.
The B-cell lymphomas segment governs the demand for non-hodgkin lymphoma therapeutics in the world, holding a massive share of over 80% in 2022.
North America is fueling the growth of the non-hodgkin lymphoma therapeutics industry, with an over one-third share in 2022.
The top players include AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, Seattle Genetics, Teva Pharmaceuticals, Takeda Pharmaceutical Company Limited, Spectrum Pharmaceuticals Inc., and Janssen Pharmaceuticals Inc.
Lymphoma therapy market is experiencing considerable demand due to the significant prevalence of numerous non-hodgkin lymphoma subtypes; recent product approvals and promising pipeline candidates from several market participants are the major market drivers.
The high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards are the major market restraints.
As prevalence is rising, more clinical trials are being conducted, and many more medications are being developed, which are the major opportunities in the non-hodgkin lymphoma therapeutics industry.